RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II...